New-onset psychosis following androgen deprivation therapy for prostate cancer.
Androgen deprivation therapy (ADT) is commonly used in the treatment of prostate cancer and is associated with several side effects including psychiatric disorders. We present an unusual case of a 62-year-old man with high risk prostate cancer that developed de novo psychosis after starting luteinizing hormone-releasing hormone (LHRH) agonists and discuss possible mechanisms to explain such findings. This case report highlights the importance of continuing assessment and monitoring of potential emotional and behavioral symptoms in prostate cancer patients treated with ADT.
Department of Oncology, Division of Radiation Oncology, Montreal General Hospital, McGill University Health Centre, Montreal, Quebec, Canada.
Daniel M
DM
Bernad
Alan
A
Dal Pra
Cintia
C
Baule
Benicio N
BN
Frey
Sergio
S
Faria
D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011605:Psychoses, Substance-Induced / Q000175:diagnosis* / Q000523:psychology; D016896:Treatment Outcome; D017329:Triptorelin Pamoate / Q000009:adverse effects* / Q000627:therapeutic use
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone